Trials / Unknown
UnknownNCT05262179
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Taejoon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of CTO0101
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTO0101 | 1 drop/ once or three times a day/ for 17 days divided into stage2 |
| OTHER | Placebo (vehicle) | 1 drop/ once or three times a day/ for 17 days divided into stage2 |
Timeline
- Start date
- 2021-10-05
- Primary completion
- 2022-05-27
- Completion
- 2022-07-05
- First posted
- 2022-03-02
- Last updated
- 2022-03-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05262179. Inclusion in this directory is not an endorsement.